𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Extent and impact of missing ADAS-cog items in ADCS clinical trials

✍ Scribed by Kimberly Schafer; Mary Sano; Paul Aisen; Michael Donohue; Chung-Kai Sun; Lon Schneider

Book ID
118467615
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
53 KB
Volume
7
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The ADAS-cog and clinically meaningful c
The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease
✍ Kenneth Rockwood; Sherri Fay; Mary Gorman πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 184 KB πŸ‘ 2 views

## Abstract ## Background A minimum 4‐point change at 6 months on the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐cog) is deemed clinically important, but this cut‐point has been little studied in relation to clinical meaningfulness. In an investigator‐initiated, clinical trial o

Visit-driven endpoints in randomized HIV
Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics
✍ Emmanuelle Le Corfec; Sylvie Chevret; Dominique Costagliola πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 133 KB

In randomized HIV/AIDS clinical trials, CD4 lymphocyte counts and plasma HIV-1 RNA measurements are often used as endpoints. The comparison between treatment groups is mainly based on a summary measure of outcome, so-called summary statistic. Such analyses are often complicated by missing data occur